<DOC>
	<DOCNO>NCT01149525</DOCNO>
	<brief_summary>The objective study evaluate efficacy L-carnitine versus placebo treatment fatigue multiple sclerosis patient . This study randomize 60 patient cross-over design . This study sponsor academic French health institution .</brief_summary>
	<brief_title>Efficacy L-carnitine Versus Placebo Treatment Fatigue Multiple Sclerosis</brief_title>
	<detailed_description>Fatigue one frequent disable symptom Multiple Sclerosis ( MS ) . L-Carnitine currently use symptomatic treatment fatigue chemotherapy patient cancer . It also empirically use numerous MS center treatment fatigue . However , practice evidence-based ( Cochrane review 2010 ) . This study evaluate efficacy L-carnitine versus placebo treatment fatigue MS patient randomize double blind national multicenter cross-over trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>18 year old old Relapsing remitting ( RR ) secondary progressive ( SP ) primary progressive multiple sclerosis accord McDonald 2005 ( Polman ) MS diagnostic criterion . Affected fatigue 3 month global score Modified Fatigue Impact Scale ( MFIS ) &gt; 45 . Indication treatment fatigue appreciation neurologist . Expanded Disability Status Scale ( EDSS ) exceed 6.0 . Information comprehensive agreement sign patient investigator . Subject affiliate health insurance coverage . Patients serious unstable disease : recurrent serious relapse rapidly ongoing disability impairment precede 6 month serious non stabilize depression Patients start new disease modify therapy , immunosuppression antidepressant therapy le 3 month ago stabilize . Patients treatment fatigue condition may interfere fatigue evaluation appreciation neurologist . Energy drink consumption toxicomania . All reason opinion neurologist may impair study management , especially patient compliance , neuropsychological disorder may input questionnaire fill . Person protection law . Participation clinical trial ( allow exception , recommendation scientific council ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Multiple Sclerosis/complications</keyword>
	<keyword>Fatigue Syndrome</keyword>
	<keyword>Chronic/drug therapy</keyword>
</DOC>